Quiero saber acerca de...

36564

Federal Register / Vol. 86, No. 130 / Monday, July 12, 2021 / Notices
Country
Title
Application No.

United States

Oligonucleotide Analogues Targeting Human LMNA NIH E04420131US16

United States
Australia
Brazil
Canada
China
Colombia
Eurasia
Europe
Hong Kong

Oligonucleotide Analogues Targeting Human LMNA
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131AU03
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131BR04
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131CA05
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131CN06
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131CO07
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131EA08
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131EP09
Methods For Treating Progeroid Laminopathies Using Oligonucleotide Analogues Targeting Human LMNA NIH E04420131HK17.
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131IN10
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131JP11
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131KR12
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131MX13
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131NZ14
Oligonucleotide Analogues Targeting Human LMNA NIH E04420131SG15

16/096,524 371national phase.
17/024,100.
2017258642.
BR1120180722790.
3,022,303.
201780040785.7.
NC2018/0012783.
201892467.
17735676.3.
19126894.5.

khammond on DSKJM1Z7X2PROD with NOTICES

India
Japan
Korea South
Mexico
New Zealand
Singapore

The patent rights in these inventions have been assigned to the Government of the United States of America, the University of Maryland, Sarepta Therapeutics, Inc, and the Progeria Research Foundation PRF, co-owners of said rights, for commercial development and marketing. The rights to be granted by NHGRI are controlled by NHGRI by virtue of co-ownership and a license received to the listed intellectual property. The prospective patent license will be for the purpose of consolidating the patent rights to PRF.
Consolidation of these co-owned rights is intended to expedite development of the invention, consistent with the goals of the Bayh-Dole Act codified as 35
U.S.C. 200212. The prospective patent license will be worldwide, exclusive, may be limited to those fields of use commensurate in scope with the patent rights, and will be sublicensable.
The subject technology pertains to modified oligonucleotides called phosphorodiamidate morpholino oligonucleotides or PMOs targeted to pre-mRNA of human LMNA Lamin A
gene. These PMOs can be used to correct aberrant splicing of LMNA gene known to be involved in HutchinsonGilford Progeria Syndrome HGPS, and could be used in treating this ultra-rare disease and related laminopathies.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404.
The prospective Exclusive Patent License will be royalty bearing and may be granted unless, within fifteen 15
days from the date of this published notice, the NHGRI Technology Transfer Office receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209
and 37 CFR part 404.
Complete applications for a license that are timely filed in response to this notice will be treated as objections to
VerDate Sep<11>2014

17:26 Jul 09, 2021

Jkt 253001

this to the grant of the contemplated exclusive patent license.
In response to this Notice, the public may file comments or objections.
Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.
License applications submitted in response to this Notice will be presumed to contain business confidential information and any release of information from these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C.
552.
Dated: June 29, 2021.
Claire T. Driscoll, Director, Technology Transfer Office, National Human Genome Research Institute, National Institutes of Health.
FR Doc. 202114702 Filed 7921; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Institute of Mental Health;
Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Advisory Mental Health Council.
The meeting will be closed to the public in accordance with the provisions set forth in sections 552bc4 and 552bc6, Title 5 U.S.C., as amended. The grant applications and/or contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant
PO 00000

Frm 00043

Fmt 4703

Sfmt 4703

Patent No.
10,822,608

201847043433.
2019508165.
1020187034615.
MX/A/2018/013157.
747685.
11201809468X.

applications and/or contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Advisory Mental Health Council.
Date: August 6, 2021.
Time: 3:00 p.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications and/or proposals.
Place: National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD 20852 Virtual Meeting.
Contact Person: Tracy Lynn Waldeck, Ph.D., Director, Division of Extramural Activities, National Institute of Mental Health, Neuroscience Center, 6001 Executive Boulevard, Room 4133, Rockville, MD 20892, 301 4806833, waldeckt@mail.nih.gov.
Information is also available on the Institutes/Centers home page:
www.nimh.nih.gov/about/advisory-boardsand-groups/namhc/index.shtml, where an agenda and any additional information for the meeting will be posted when available.
Catalogue of Federal Domestic Assistance Program No. 93.242, Mental Health Research Grants, National Institutes of Health, HHS
Dated: July 7, 2021.
Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy.
FR Doc. 202114737 Filed 7921; 8:45 am BILLING CODE 414001P

DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Closed Meeting Pursuant to section 10d of the Federal Advisory Committee Act, as amended, notice is hereby given of a meeting of the National Heart, Lung, and Blood Advisory Council.
The meeting will be closed to the public in accordance with the
E:FRFM12JYN1.SGM

12JYN1